MedTrace Logo

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

NCT03886779 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2019-04-01

No results posted yet for this study

Summary

Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (nepafenac Ophthalmic Suspension) 0.3% QD with extra (pulse) dose on day of surgery for Treatment of Ocular Inflammation Associated with Cataract Surgery

Conditions

  • Treatment of Ocular Inflammation Associated With Cataract Surgery

Interventions

DRUG

Bromfenac

0.7 MG/ML \[Prolensa\]

DRUG

Nepafenac

3 MG/ML \[Ilevro\]

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Churchhill Communications

    collaborator UNKNOWN

  • Statistics & Data Corporation

    collaborator INDUSTRY

  • Silverstein Eye Centers

    lead OTHER

Principal Investigators

  • Steven M Silverstein, MD · Silverstein Eye Centers

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-30
Primary Completion
2017-02-15
Completion
2019-03-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886779 on ClinicalTrials.gov